1. Home
  2. WNEB vs MDWD Comparison

WNEB vs MDWD Comparison

Compare WNEB & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$12.61

Market Cap

259.2M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.51

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNEB
MDWD
Founded
1853
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Savings Institutions
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.2M
238.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
WNEB
MDWD
Price
$12.61
$18.51
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$11.00
$37.50
AVG Volume (30 Days)
55.0K
83.4K
Earning Date
01-27-2026
11-20-2025
Dividend Yield
2.22%
N/A
EPS Growth
27.15
N/A
EPS
0.66
N/A
Revenue
$79,080,000.00
$20,932,000.00
Revenue This Year
N/A
$15.89
Revenue Next Year
$7.48
$25.33
P/E Ratio
$19.24
N/A
Revenue Growth
9.08
6.15
52 Week Low
$7.63
$14.14
52 Week High
$13.95
$22.51

Technical Indicators

Market Signals
Indicator
WNEB
MDWD
Relative Strength Index (RSI) 46.57 50.09
Support Level $13.20 $18.55
Resistance Level $13.51 $19.00
Average True Range (ATR) 0.34 0.53
MACD -0.11 -0.05
Stochastic Oscillator 1.79 23.95

Price Performance

Historical Comparison
WNEB
MDWD

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: